Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025.

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

There’s plenty of empty lab space around Greater Boston these days, and a lot of competition for life-science tenants. Now Ginkgo Bioworks is throwing some space in the Seaport it doesn’t need right ...

Ginkgo Bioworks falls short on Q4 revenue and projects weak 2025 guidance. Learn about DNA stock's valuation risks, cash reserves, and financial outlook.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Ginkgo Bioworks (DNA) is down -12.5%, or -$1.29 to $9.00.Discover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Pre-earnings options volume in Ginkgo Bioworks (DNA) is normal with calls leading puts 8:5. Implied volatility suggests the market is ...

Ginkgo’s headquarters at 27 Drydock Ave. spans some 320,000 square feet, with leases that run from 2030 through 2036. The ...